GLOBAL EXPERT EXCHANGE

08:00 – 10:00

Catheter-based treatment of hypertension, heart failure and beyond – where do we stand, where do we go?

CHAIRMAN:
Felix Mahfoud
Horst Sievert

MODERATOR:
Thomas Zeller
Paul Sobotka
Roland Schmieder
Michael Böhm
Oliver Vonend

09:24 – 09:31
Blood pressure-lowering interventions beside renal denervation – what is on the horizon?
Horst Sievert

09:17 – 09:24
Turn the page for hypertension and lets go for heart failure and arrhythmias
Michael Böhm

09:10 – 09:17
Going to the source: A disruptive approach to renal denervation with the non-vascular Verve system
Richard Heuser

09:31 – 09:38
Treatment of resistant hypertension by creation of an AV anastomosis: the pathophysiologic basis and principle of treatment
Paul Sobotka

09:38 – 09:45
Orchestrating sympathovagal balance with Barostim
Navid Madershahian

09:52 – 10:00
Discussion and conclusion

09:45 – 09:52
Barostim: Clinical evidence in resistant hypertension and heart failure
Jochen Müller-Ehmsen

09:03 – 09:10
Preliminary results of RETREAT (renal denervation with ultrasound after failed radiofrequency denervation)
Horst Sievert

08:56 – 09:03
Late results of radiofrequency denervation and assessment of vessel patency
Yvonne Bausback

We are asking all faculty members to strictly respect the given time limits.
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:21</td>
<td>What to learn from recent clinical trials: Symplicity HTN-3, FRENCH-DENERV-HTN, PRAGUE-15?</td>
<td>Thomas Zeller</td>
</tr>
<tr>
<td>08:14</td>
<td>How does renal artery anatomy effect the outcome of RDN procedures?</td>
<td>Britta Vogel</td>
</tr>
<tr>
<td>08:07</td>
<td>From bench to bedside: how and where to treat the renal artery?</td>
<td>Felix Mahfoud</td>
</tr>
<tr>
<td>08:28</td>
<td>Renal denervation – dead or alive? The view point of a nephrologist/hypertenoion specialist</td>
<td>Oliver Vonend</td>
</tr>
<tr>
<td>08:35</td>
<td>Recent clinical findings and how they changed my patient selection: who is the ideal candidate?</td>
<td>Philipp Lurz</td>
</tr>
<tr>
<td>08:49</td>
<td>Renal denervation in patients with impaired kidney function – results from the Heidelberg RDN registry</td>
<td>Erwin Blessing</td>
</tr>
<tr>
<td>08:42</td>
<td>What is needed now? New clinical trials that would change my clinical practice</td>
<td>Roland Schmieder</td>
</tr>
<tr>
<td>08:00</td>
<td>Renal denervation: what has anatomy taught us?</td>
<td>Renu Virmani</td>
</tr>
</tbody>
</table>

We are asking all faculty members to strictly respect the given time limits.
## MAIN ARENA 1

**15:00 – 16:30**  
**VIVA @ LINC: Renal and visceral disease: pressing new dilemmas and pushing the field forward**  
**CHAIRMAN:** Chris Metzger  
**MODERATOR:** Michael Jaff  
Tony Das  
Peter Schneider  
**Felix Mahfoud**  
Michael Moche  
Jos van den Berg  
Henrik Schröder

15:49 – 16:14  
Live case transmission from Teaneck

16:14 – 16:22  
Visceral artery aneurysms. The silent killer comes into focus now that we can find them and fix them  
**Michael Dake**

16:22 – 16:30  
Discussion and conclusion

15:41 – 15:49  
Endovascular treatment of mesenteric angina: Tips, tricks, and techniques  
Chris Metzger

15:33 – 15:41  
How to assess the hemodynamic importance of a renal artery stenosis  
**Felix Mahfoud**

15:05 – 15:13  
CORAL trial aftermath: What do we do now? Renal revascularisation in perspective  
**Michael Jaff**

15:13 – 15:33  
Live case transmission from Teaneck

15:00 – 15:05  
Introduction by the chairman

---

We are asking all faculty members to strictly respect the given time limits.
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:30 – 15:00</td>
<td>Latest insights from cardiovascular clinical trials</td>
<td>CHAIRMAN: William Gray</td>
</tr>
<tr>
<td></td>
<td></td>
<td>MODERATOR: Felix Mahfoud</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Dietrich Pfeiffer</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Dariusz Dudek</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Joachim Schofer</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Christian Etz</td>
</tr>
<tr>
<td>14:22 – 14:41</td>
<td>Live case transmission from Leipzig</td>
<td></td>
</tr>
<tr>
<td>14:48 – 14:55</td>
<td>Current status of ablation therapy for atrial fibrillation</td>
<td>Philipp Sommer</td>
</tr>
<tr>
<td>14:55 – 15:00</td>
<td>Discussion and conclusion</td>
<td></td>
</tr>
<tr>
<td>14:17 – 14:22</td>
<td>Cerebral protection during TAVI – the CLEAN-TAVI trial</td>
<td>Stephan Hausig</td>
</tr>
<tr>
<td>14:10 – 14:17</td>
<td>Echocardiographic criteria for favourable TAVI outcome – can we predict the risk?</td>
<td>Andreas Hagendorff</td>
</tr>
<tr>
<td>13:37 – 13:42</td>
<td>Review of results of the European, randomized trial of AV anastomosis with the ROX coupler for resistant hypertension</td>
<td>Paul Sobotka</td>
</tr>
<tr>
<td>13:42 – 14:03</td>
<td>Live case transmission from Leipzig Heartcenter</td>
<td></td>
</tr>
<tr>
<td>14:03 – 14:10</td>
<td>The role of TAVI in high-risk and normal-risk patients</td>
<td>Joachim Schofer</td>
</tr>
</tbody>
</table>

We are asking all faculty members to strictly respect the given time limits.